Pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants
Zhou, Y.; MENG, X.; Li, J.; Wang, J.; Zeng, G.; Cao, Y. R.; Hu, C.; Jin, R.
Show abstract
To explore novel treatment/prevention of COVID-19, a novel broad-spectrum neutralizing antibody injection, anti-SARS-CoV-2 antibody SA55 Injection (SA55 injection) was developed. Pharmacokinetics (PK) characteristics of SA55 injection were evaluated in a randomized, controlled, double-blind phase {square} trial based on healthy participants aged 18-65 years. PK parameters (AUC0-{infty}, AUC0-t, and Cmax) were assessed using one-way ANOVA and the Power model. Results demonstrated that SA55 injection with a Tmax of 12.6 days and a half-life of 103 days. In conclusion, the SA55 injection demonstrates potential for use in the prevention of COVID-19 infection.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis 94%
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 92%
- Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China 92%
Similar papers in this journal
- Establishing defined daily doses (DDDs) for antimicrobial agents used for pigs, cattle and poultry in Japan and comparing them with European DDD values 94%
- Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: a three-part randomized, double-blind, placebo-controlled trial 94%
- Stability of extemporaneously compounded amiloride nasal spray 94%
Similar papers in this journal
- Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial 97%
- Randomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine – A Study Protocol 94%
- Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 93%
Similar papers in this journal
- Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro 94%
- Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial 94%
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 94%
Similar papers in this journal
- Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2 94%
- Adverse events following COVID-19 vaccination in young Japanese people: A case-control study of the risk of systemic adverse events by a questionnaire surveyShort title: COVID-19 vaccine adverse events in young Japanese 93%
- Adverse events following COVID-19 virus vaccination in Japanese young population: The first cross-sectional study conducted by a questionnaire survey after the first-time-injection 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.